CA2192456C - Pyridylbisphosphonates for use as a therapeutical agent - Google Patents
Pyridylbisphosphonates for use as a therapeutical agent Download PDFInfo
- Publication number
- CA2192456C CA2192456C CA002192456A CA2192456A CA2192456C CA 2192456 C CA2192456 C CA 2192456C CA 002192456 A CA002192456 A CA 002192456A CA 2192456 A CA2192456 A CA 2192456A CA 2192456 C CA2192456 C CA 2192456C
- Authority
- CA
- Canada
- Prior art keywords
- pyridinyl
- methylidene
- amino
- bisphosphonic acid
- acid tetraethylester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
Abstract
The present invention relates to certain optionally ring substituted pyridinylaminomethylidene bisphosphonic acid tetralkyl esters (I) and their use for the treatment of bone diseases, such as osteolytic bone diseases due to malignancy, Paget's disease and primary and secondary osteoporosis.
Description
wo 9sr~3as6 rc~r~ssrooais z ~ gz~56 PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL
AGENT
The present invention relates to a specific group of pyridyIbisphosphonic acid tetraesters for use as a therapeutical agent, in particular for use in bone diseases.
Bisphosphonates are therapeutic agents for the treatment of pathological bone 1o destruction of various origins, such as osteolytic bone diseases due to malignancy, Paget's disease, and osteoporosis. They are analogues of the physiologically occur-ring inorganic pyrophosphates. The basic P-C-P structure of the bisphosphonates makes it possible to form a great number of different compounds either by chan-ging the side chains of the carbon atom or by an addition onto the phosphates.
In general, bisphosphonates inhibit osteoclasts, cells, which are responsible for the bone resorption. Known bisphosphonates bound to the bone matrix enter resorting osteoclasts and reduce the activity of osteoclasts. They inhibit bone resorption both in vitro and in vivo. Limited absorption from the gastrointestinal tract, fast disap-2 a pearance in bone tissue, and unchanged excretion in urine are all characteristics of known bisphosphonates.
The present innovation is based on the idea of providing bisphosphonate derivati-ves with high oral bioavailability and with low affinity to bone. This is to avoid 25 side-effect without loosing the antiresorptive activity.
In the patents US 4,447,256, DE 28 31 578 (Suzuki et al.); JP 55089210, JP
55098105, JP 55043054, 1P 55043055 (Nissan Chemical industries) a process is disclosed for the preparation of some pyridylaminomethylenebisphosphonic acid 3 o tetraalkylesters. According to the patents the compounds may be used as herbici-des.
In the patent EP 337 706 (Isomura et al.) the preparation of cyclyl- or heterocyclyl substituted aminomethylenebisphosphonic acid tetraesters is disclosed, wherein the 35 ring substituent is either partly or Fully saturated. The tetraesters were not tested.
z~ ~z4~6 In the patent US 4,973,576 (Sakamoto et al.) some isox- awlyl substituted aminoimethylenebisphosphonic acid tetraalkylesters are disclosed, but they have basicly been tested in arthritis. Their oral bioavailability is low.
In the patent EP 282 309 azole-aminomethylenebisphosphonic acids and lower alkyl esters are disclosed. The tetraesters were not tested.
In the patent EP 325 482 cycloalkyl-aminomethylenebisphosphonic acids and esters are disclosed. The tetraesters were not tested.
The present invention is directed at a group of pyridylbisphosphonates with new pharmacological and pharmacoldnetic profiles. These new pyridylbisphosphonates do not inhibit bone resorption in vitro but they inhibit bone resorption in vivo.
Pyridylbisphosphonates do not bind to bone matrix and they seem to need metabo-lic activation.
The invention thus concerns pyridyl-aminomethylenebisphosphonic acid tetraal-lrylesters, which are optionally substituted at the pyridine ring, specifically methy-lenebisphosphonic acid derivatives of the general formula I
O
~~ / ORt ~NH ~ / P ~ OR2 N
Y H/C~P /0R3 ~~ ~ OR4 O
WO 95/33466 219 Z 4 5b P~~~00315 in which formula each of the groups R, to R4 is straight or branched saturated C,-Cs-alkyl group, each of X and Y is independently hydrogen, straight or branched saturated C;
Cs -alkyl group, halogen, hydroxyl, CI-Cs-alkoxy, benzyloxy, acyloxy, vitro, tritluoro-methyl group or NRsRb, wherein Rs and R6 are the same or different and are hydrogen, C,-Cs-alkyl or -acyl, for use as therapeutically active agents.
The groups X and Y, as well as the amino group of the methylenebisphosphonic 1o acid ester frame can substitute any one of the positions 2 to 6 of the pyridyl ring.
The groups X and Y are preferably hydrogen or hydroxyl groups, in the latter meaning one or two hydroxyl groups being preferred. The pyridinyl group is preferably a 2-pyridinyl group.
Halogen is fluorine, chlorine, bromine or iodine.
The CI Cs-alkyl group is straight or branched, such as methyl, ethyl, n-, i-propyl, n-, i- and t-butyl, or -pentyl, preferably methyl or ethyl. The alkyl group in the alkoxy group as defined for X and Y can have the meaning given above, and is 2 o preferably methyl or ethyl.
Acyl in the definition of acyloxy as X and Y, or in the definition of Rs or R6, is preferably a lower alkyl carbonyl group, wherein the alkyl group contains from 5 C-atoms and has the meaning given above, and is preferably methyl or ethyl.
The groups RI to Ra are preferably the same, and advantageously ethyl.
Preferred compounds of the present invention are the compounds identified as fol-lows:
[(2-pyridinylamino)methylidene]bisphosphonic acid tetraethylester 3 0 [[(3-Hydroxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [j(6-Methoxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [(4-Pyridinylamino)methylidene]bisphosphonic acid tetraethylester [[(5-Chloro-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [j(5-Methoxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [j(6-Amino-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester , [((3-Nitro-2-pyridinyl)amino]methylidene]bisphosphonicacid tetraethylester j[(3,5-Dichloro-2-pyridinyl)amino]methylidene]bisphosphonicacid tetraethylester [[(6-Hydroxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(5-Hydroxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester j[(3-Chloro-5-tritluoromethyl-pyridinyl)amino)methylidene]-bisphosphonic acid tetraethylester [[(2-Chloro-3-pyridinyl)aminio]methylidene]bisphosphonic acid tetraethylester [[(6-Chloro-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(3-Benzyloxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(5-Nitro-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(5-Benzyloxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester is The N-substituted (aminoalkylidene)bisphosphonic acid tetraesters may be prepared in a known manner e.g. by reacting an amino substituted compound with alkyl orthoformate and reacting the imino ether derivative obtained as an intermediate with dialkyl phosphite, either as such or in purified form.
In a second method, a suitable aminopyridine is first reacted with a mixture of formic acid/acetic anhydride. The obtained formamide is then reacted with phos-phorus trihalogenide and trialkylphosphite.
Aminoallrylidenebisphosphonic acid tetraesters may also be prepared by letting a aminopyridine derivative react with a halomethylphosphonate and the thus obtained compound, after bromination, is reacted with trialkylphosphite (Schrader et al. Synthesis (1986), 372).
3 o The compounds are useful for the treatment of bone diseases, such as osteolytic bone diseases due to malignancy, Paget's disease and primary and secondary oste-oporosis, in a mammal.
The activity of the compounds was verfied by animal and in vitro studies, the methods and results of which are presented below. In normal growing rats, a representative compound, [(2-pyridinylamino)methylidene]bisphosphonic acid tetra-ethylester, decreased spontaneous bone resorption as assessed by urinary tetracy-5 cline excretion from chronically prelabeled rats. The said compound was also effective in preventing bone loss in experimental osteoporosis induced by sciatic nerve section in rats. No effect in vitro on resorption of mice calvaria in culture, assayed by calcium release was shown. This may suggest that the compound is metabolized before pharmacological effects can be found. The parent compound 1o did not show either any binding on hydroxyapatite crystals in vitro.
Pharmacoldnetics of the compound j(2-pyridinylamino)methylidene]bisphosphonic acid tetraethylester was studied in rats. Minor amounts of an intravenous dose was excreted as a parent compound during 24 hours into urine supporting extensive metabolism as well. About half of the oral dose of the said compound was ab-sorbed in rats.
W095133466 21924-5 b P~~5J00315 The followingexamples illustrate the present invention without limiting the same in any way.
Example 1 Synthesis of [(2-Pyridinylamino)methylidene]bisphosphonic acid tetraethylester:
2-Aminopyridine (0.2 moles) was mixed with triethyl orthoformate (0.8 mol) and boron trifluoride etherate and the mixture was heated at 150° C for 4h, whereafter to the ethanol formed in the reaction was distilled off. Triethylorthoformate was distilled off in vacuum. Diethylphosphite (0.4 mol) was added to the reaction mixture, and the mixture was heated at 150° C while distilling off the ethanol formed. The mixture was cooled and the raw product was purified chromato-graphically (eluent dichloromethane-methanol 1:1). Yield 29 g (37%).
The physico-chemical characteristics of this product are as follows:
"P-NMR (CDCI,) 15.52 ppm 'H-NMR (CDC13):
2 ppm Protons Multiplicity Assignation o 1.27 12H m CH;
4.21 8H m CHz 4.78 1H - d NH
5.57 1H dt CH
6.52 1H d CH Carom) 6.67 1H m CH (arum) 7.44 1H m CH (arum) 8.11 1H d CH Carom) ,. CA 02192456 2005-03-24 wo 9sr~4ss ~ rcr~sroo3ts Mass Spectrum (Ei Mass): .
334 M- I:tOH
243 M- P(O)(OCiHs)z F.xampk 2 Preparation of [[(5-Chloro-2-pyridinyl)amino]methylidene]-bisphosphonic acid io 5-chloro-2-amir~opyridine (0.2 moles) was mixed with triethyl orthoformate (0.8 mol) _.
and boron trifluoride etherate and the mixture was heated at 150° C for 4 h. The formed ethanol was distilled off during the reaction. Triethylorthoformate was distilled off in vacuum. Diethylphosphibe (0.4 mol) was added to the reaction mixture, and the mixt<u~e was .heated at 150° C while disrOling off the ethanol formed. The mixture was cooled and the raw product was purified chmmato-graphically (eluent dichloromdhane-methanol, 1:1). Yield 26.5 g (32 96). (31-P-NMR 15.20 ppm; CDCI~
2 o In the same manner may be pfd:
[[(3,5-dichIoro-2-pyridinyl)amino]methylidene]bisphosphonic acid tettsethylester (31-P-NMR 14.59 ppm; CDCI~
2 s [[(3-Chloro-S-trifluorom~hyl-pyridinyl)amino]m~hylidene]- bisphosphonic acid tetraexhylester (31-P-NMR 14.15 ppm; CDCI~
[[(5-Hydroxy-2-pyridinyl)amino]methylideae]bisphosphonic acid tetraethylester (Mass Spoctrum (EI Mass): 396 M, 35D M- EtOH, 259 M P(O)(OC=H')~
[[(5-Nitro-2-pyridinyl)amino]methylidene)bisphosphonic acid tetraethylestes (31-P-NMR 13.97 ppm; CDCIs) wo ~ pcrr~sroo3is a [(5-Benzyloxy-2 pyridinyl)amino]methylidene]bisphosphonic acid retiaethylester [[(5-Methaxy 2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(3,5-Dimethaay 2 pyridinyl)amino]methylidene]bisphos phonic acid taraethyles-ter F~amltle 3 1 o Preparation of [[(3-Hydtnxy-2 pyridinyl~nino]methylidene]-bisphosphonic acid tettaetbylester 2-Amino-3-hydroxypyridine was O-ba~zylated with beazylchloride in a two phase system and phase transfer catalyst (&istol et al, Synthesis 1981, 971). 2-Amino-3-' benzyloxypyridine (0.I mol) was dissolved in dichio~romethana and the solution was cooled tow0° C 50 ml Formic acid/axxicanhydride (5:3) was addod to the solution, and the mixture was slimed overnnght at room temperature. The reaction mixture was abated, and the residue was washed with di-isopt~opyldher to give 11.4 g 3-benzyloxypyridinyl-2-formamide. 10 ml Phosghoroustrichloride and 1.5 ml 2o triethylphosphite was heated at 60° -?0° C for 1 hour. 3-Henzyloxygyridyl-2-formamide (0.01 mol) was addod to the solution, and the mixture was stir~d far five hours at room tangaature. The ion mixture was cmroentrated and puri-fied chromatogtaphicallY (eluent dichloromethane-mahanol, 2:1) to get 0.8 g [
f (3-benzyloxy 2 pyridinylo]methylidene]bisphosphorcic acid tetiraethylester. The benzylgroug was hydrogenated to get 0.4 g [[(3-Hydroxy 2 pyridinyl)amino]methy-lidene]-bisphosphonic acid Z~thylesOes (Mass Spearum (LI Mass): 396 M, 350 M- EtOH, Z59 M- P(O)(z In the same manner may be prepared:
[[(6-Benzyloxy 3-pyridinyl)amino]methylidene]bisphosphonic acid tetracthylester WO 95133466 pCTIF195100315 j[(6-Hydroxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester Example 4 Preparation of [[(6-Chloro-3-pyridinyl)amino]methylidene]-bisphosphonic acid tetraethylester Diethyl iodomethylphosphonate was prepared according to Cade, J. Chem.Soc.
1959; 2266.
to 6-Chloro-3-aminopyridine was alkylated with diethyl iodomethylphosphonate, sodium amide as base, with lrnown methods. The obtained 6-chloro-3-pyridinyla-mino-methylphosphonic acid diethylester (0.5 mol) and N-bromosuccinimid (0.5 mot) in anhydrous carbontetrachloride is irradiated 2 hours with a 200 W lamp.
The solid is filtered off, washed with carbontetrachloride and the solution is con-centrated in vacuo. The obtained 6-chloro-3-pyridinylamino(bromomethyl)-phos-phonic acid diethylester (0.1 mol) is warmed in tetrahydrofuran with triet-hylphosphite (0.1 moI) in 50° C for 4 hours. The reaction mixture is concentrated in vacuo. The product is purified chromatographically (eluent dichloromethane:
2o methanol 9:1). Yield 5.1 g.
In the same manner may be prepared:
jj(2-Chloro-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(6-Methoxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [(4-Pyridinylamino)methylidene]bisphosphonic acid tetraethylester 3 o j[(6-Amino-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(3-Nitro-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(2-Chloro-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(5-Acyloxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester r Effect on spontaneous bone resorption assessed by urinary tetracycline excreti-on from prelabeled rats Male Sprague-Dawley rats were used. From the first week of life, the rats were 1o injected subcutaneously with a solution containing 10 WCi/ml of (7-'H(I~)tetracy-cline dissolved in physiological saline. The injections were performed twice week-ly for 6 weeks. Every animal received a total amount of 20 ~Ci radiolabeled tetracycline. All animals were given normal diet for growing animals and water ad libitum. One week after the last injection of radiolabeled tetracycline, the rats were >.5 weighed and feeding with diet for adult animals was started. At fifth day the rats were randomized into groups and housed in individual metabolic cages. 24-h urine collections were performed for ten days. From the second day [(2-pyridinylami-no)methylidene]bisphosphonic acid tetraethylester, compound I, dissolved in phy-siological saline was injected subcutaneously at different dose levels daily for six 2 o days. Control animals received physiological saline. Urine volume was measured and the radioactivity in urine samples was determined by liquid scintillation coun-ting. The data was calculated as the ratio of treated/control at each day for the determination of maximal inhibition of tetracycline excretion.
25 Excretion of unmetabolized tetracycline into urine reflects its removal from bone during resorptive processes and thus enables the continual monitoring of bone resorption. As shown in Table 1 (compound I) dose-dependently inhibited exc-rrztion of radiolabeled tetracycline indicating inhibition of bone resorption.
W095133466 2~ 92456 pCT~5100315 Table 1 Effect on spontaneous bone resorption in rats Inhibition of tetracycline excretion ' n Mean (SE) I 1 mg/kg 5 12.2 (6.4) 10 mglkg 5 19.8 (5.9) 100 mg/kg 5 50.0 (6.1) 200 mg/kg 5 72.9 (2.~
Effect on immobilization induced osteoporosis in rats Male Sprague-Dawley rats weighing 200125 g were randomized by weight into groups and anesthetized with Hypnorm/Mebunat and Temgesic. A dorsolateral to incision was made on the right or left hip through which the sciatic nerve was exposed, and a 0.5 cm section excised. The muscle and skin were sutured and the animal returned to its cage. The contralateral leg was left intact. The compound I
dissolved in physiological saline was administered by subcutaneous injection daily at different dose levels from two days before the surgery until the day of 20 postneurectomy. Control animals received physiological saline. Animals double-labeled with fluorochrome at standardized time points were sacrificed at 21 days postneurectomy and their femora were removed. Femora were embedded in met-hylmetacrylate, sectioned, and stained. The metphyseal secondary spongiosa and the diaphyseal cortical bone of the femora were subjected to histomorphometric 2 o analysis. In control rats, femoral total bone area decreased in the immobilized leg.
As shown in Table 2 the compound I increased dose-dependently femoral bone area in the immobilized leg. No deleterious effects on mineral apposition rate of cortical bone were shown (data not presented).
wo ~~ss rcr~oo3is Table 2 ,Effect on immobilization induced osteoporosis in rats . Immobilized , leg Femur total bone area 96 , , n Mean (SE) Control 20 5.3 (O.ti) I 1 mglkg 4 6.0 (1.3) 37,5 mglkg 5 17.3 (2.0) ' 75 mg/kg 5 ' 24.5 (2.5) .200 mg/kg 7 . 35.5 (1.7) 1o Et~ect on bone in vitro Newborn mitt were labeled by a subcutaneous injection of 'sCa four days prior to saciifioe. Calvarial bone fragtneats were miaodissected from the parietal bones, prancubated in culture medium with indomethaein, washed and then cultured for three days with and without the compound I. Hone resorption was stimulated by parathyroid hormone (PT~i, 10 nM) and an intubitory effect on this stimulated resorption was measured. As presaited in Table 3 no inhibition of resorption in vitro was shown except at very high, unphyaiological eonc~trations. For the determination of the binding of compound I to bone mineral, '4C-disodium elod-2 G ronate tetrahydrate and hydroxyapatite crystals were incubated at room temperature in barbituric acid buffer at physiological pH in the absence and pea of the compound I in various concentrations. Aftea two hours incubation, the mixture was centrifuged, and the percent of the total specifically bound radioactivity was measured from the supernatant. No binding of the compound I to hydroxyapatite W095/33466 2192456 P~~~00315 was found at up to 500 ~cM concentration (Table 3).
Table 3 Effect on bone in vitro Inhibition of PT'II-sti-Binding to bone mulated resorption mineral 100 (PTH-x)/PT'fi Inhibition R'o (SE) I 1 ~cmolll No inhibiton N.D.
5 pmol/I N.D. No binding 10 ~.mol/1 No inhibition N.D.
100 pmol/I No inhibition No binding 200 ~mol/l N.D. No binding 500 pmol/1 N.D. No binding 1000 ~.mol/112.9 (1.3) N.D.
N.D. = Not determined Pharmacokinetics Bioavailability was determined from the total amount of compound excreted into urine during 24 hours or from the serum concentration data at different time points after oral administration and intravenous administration. The urine and serum samples were analyzed for the test compound I with high pressure liquid chroma-tographic methods. Below 10Y~ of the oral dose and 14% of the intravenous dose was excreted as a parent compound during 24 hours (Table 4, bioavailability 5$%). BioavaiIability of compound I assessed by serum concentration data was 44~.
WO 95133466 PCT1Fd95/00315 z~ 9za.56 Table 4 Urinary excretion, AUCa,m, and bioavailability of I
after a single intravenous or oral dose*
Excretion AUCo-, ~, 0-24 h '3'0 of doseF % h * ~g/ml F % , p.o. 7.8 58 60.7 44 i.v. 13.6 138.7 Dose 114 mg/kg F = bioavailability to AUC0.,~, = Area under the blood level-time curve
AGENT
The present invention relates to a specific group of pyridyIbisphosphonic acid tetraesters for use as a therapeutical agent, in particular for use in bone diseases.
Bisphosphonates are therapeutic agents for the treatment of pathological bone 1o destruction of various origins, such as osteolytic bone diseases due to malignancy, Paget's disease, and osteoporosis. They are analogues of the physiologically occur-ring inorganic pyrophosphates. The basic P-C-P structure of the bisphosphonates makes it possible to form a great number of different compounds either by chan-ging the side chains of the carbon atom or by an addition onto the phosphates.
In general, bisphosphonates inhibit osteoclasts, cells, which are responsible for the bone resorption. Known bisphosphonates bound to the bone matrix enter resorting osteoclasts and reduce the activity of osteoclasts. They inhibit bone resorption both in vitro and in vivo. Limited absorption from the gastrointestinal tract, fast disap-2 a pearance in bone tissue, and unchanged excretion in urine are all characteristics of known bisphosphonates.
The present innovation is based on the idea of providing bisphosphonate derivati-ves with high oral bioavailability and with low affinity to bone. This is to avoid 25 side-effect without loosing the antiresorptive activity.
In the patents US 4,447,256, DE 28 31 578 (Suzuki et al.); JP 55089210, JP
55098105, JP 55043054, 1P 55043055 (Nissan Chemical industries) a process is disclosed for the preparation of some pyridylaminomethylenebisphosphonic acid 3 o tetraalkylesters. According to the patents the compounds may be used as herbici-des.
In the patent EP 337 706 (Isomura et al.) the preparation of cyclyl- or heterocyclyl substituted aminomethylenebisphosphonic acid tetraesters is disclosed, wherein the 35 ring substituent is either partly or Fully saturated. The tetraesters were not tested.
z~ ~z4~6 In the patent US 4,973,576 (Sakamoto et al.) some isox- awlyl substituted aminoimethylenebisphosphonic acid tetraalkylesters are disclosed, but they have basicly been tested in arthritis. Their oral bioavailability is low.
In the patent EP 282 309 azole-aminomethylenebisphosphonic acids and lower alkyl esters are disclosed. The tetraesters were not tested.
In the patent EP 325 482 cycloalkyl-aminomethylenebisphosphonic acids and esters are disclosed. The tetraesters were not tested.
The present invention is directed at a group of pyridylbisphosphonates with new pharmacological and pharmacoldnetic profiles. These new pyridylbisphosphonates do not inhibit bone resorption in vitro but they inhibit bone resorption in vivo.
Pyridylbisphosphonates do not bind to bone matrix and they seem to need metabo-lic activation.
The invention thus concerns pyridyl-aminomethylenebisphosphonic acid tetraal-lrylesters, which are optionally substituted at the pyridine ring, specifically methy-lenebisphosphonic acid derivatives of the general formula I
O
~~ / ORt ~NH ~ / P ~ OR2 N
Y H/C~P /0R3 ~~ ~ OR4 O
WO 95/33466 219 Z 4 5b P~~~00315 in which formula each of the groups R, to R4 is straight or branched saturated C,-Cs-alkyl group, each of X and Y is independently hydrogen, straight or branched saturated C;
Cs -alkyl group, halogen, hydroxyl, CI-Cs-alkoxy, benzyloxy, acyloxy, vitro, tritluoro-methyl group or NRsRb, wherein Rs and R6 are the same or different and are hydrogen, C,-Cs-alkyl or -acyl, for use as therapeutically active agents.
The groups X and Y, as well as the amino group of the methylenebisphosphonic 1o acid ester frame can substitute any one of the positions 2 to 6 of the pyridyl ring.
The groups X and Y are preferably hydrogen or hydroxyl groups, in the latter meaning one or two hydroxyl groups being preferred. The pyridinyl group is preferably a 2-pyridinyl group.
Halogen is fluorine, chlorine, bromine or iodine.
The CI Cs-alkyl group is straight or branched, such as methyl, ethyl, n-, i-propyl, n-, i- and t-butyl, or -pentyl, preferably methyl or ethyl. The alkyl group in the alkoxy group as defined for X and Y can have the meaning given above, and is 2 o preferably methyl or ethyl.
Acyl in the definition of acyloxy as X and Y, or in the definition of Rs or R6, is preferably a lower alkyl carbonyl group, wherein the alkyl group contains from 5 C-atoms and has the meaning given above, and is preferably methyl or ethyl.
The groups RI to Ra are preferably the same, and advantageously ethyl.
Preferred compounds of the present invention are the compounds identified as fol-lows:
[(2-pyridinylamino)methylidene]bisphosphonic acid tetraethylester 3 0 [[(3-Hydroxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [j(6-Methoxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [(4-Pyridinylamino)methylidene]bisphosphonic acid tetraethylester [[(5-Chloro-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [j(5-Methoxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [j(6-Amino-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester , [((3-Nitro-2-pyridinyl)amino]methylidene]bisphosphonicacid tetraethylester j[(3,5-Dichloro-2-pyridinyl)amino]methylidene]bisphosphonicacid tetraethylester [[(6-Hydroxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(5-Hydroxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester j[(3-Chloro-5-tritluoromethyl-pyridinyl)amino)methylidene]-bisphosphonic acid tetraethylester [[(2-Chloro-3-pyridinyl)aminio]methylidene]bisphosphonic acid tetraethylester [[(6-Chloro-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(3-Benzyloxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(5-Nitro-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(5-Benzyloxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester is The N-substituted (aminoalkylidene)bisphosphonic acid tetraesters may be prepared in a known manner e.g. by reacting an amino substituted compound with alkyl orthoformate and reacting the imino ether derivative obtained as an intermediate with dialkyl phosphite, either as such or in purified form.
In a second method, a suitable aminopyridine is first reacted with a mixture of formic acid/acetic anhydride. The obtained formamide is then reacted with phos-phorus trihalogenide and trialkylphosphite.
Aminoallrylidenebisphosphonic acid tetraesters may also be prepared by letting a aminopyridine derivative react with a halomethylphosphonate and the thus obtained compound, after bromination, is reacted with trialkylphosphite (Schrader et al. Synthesis (1986), 372).
3 o The compounds are useful for the treatment of bone diseases, such as osteolytic bone diseases due to malignancy, Paget's disease and primary and secondary oste-oporosis, in a mammal.
The activity of the compounds was verfied by animal and in vitro studies, the methods and results of which are presented below. In normal growing rats, a representative compound, [(2-pyridinylamino)methylidene]bisphosphonic acid tetra-ethylester, decreased spontaneous bone resorption as assessed by urinary tetracy-5 cline excretion from chronically prelabeled rats. The said compound was also effective in preventing bone loss in experimental osteoporosis induced by sciatic nerve section in rats. No effect in vitro on resorption of mice calvaria in culture, assayed by calcium release was shown. This may suggest that the compound is metabolized before pharmacological effects can be found. The parent compound 1o did not show either any binding on hydroxyapatite crystals in vitro.
Pharmacoldnetics of the compound j(2-pyridinylamino)methylidene]bisphosphonic acid tetraethylester was studied in rats. Minor amounts of an intravenous dose was excreted as a parent compound during 24 hours into urine supporting extensive metabolism as well. About half of the oral dose of the said compound was ab-sorbed in rats.
W095133466 21924-5 b P~~5J00315 The followingexamples illustrate the present invention without limiting the same in any way.
Example 1 Synthesis of [(2-Pyridinylamino)methylidene]bisphosphonic acid tetraethylester:
2-Aminopyridine (0.2 moles) was mixed with triethyl orthoformate (0.8 mol) and boron trifluoride etherate and the mixture was heated at 150° C for 4h, whereafter to the ethanol formed in the reaction was distilled off. Triethylorthoformate was distilled off in vacuum. Diethylphosphite (0.4 mol) was added to the reaction mixture, and the mixture was heated at 150° C while distilling off the ethanol formed. The mixture was cooled and the raw product was purified chromato-graphically (eluent dichloromethane-methanol 1:1). Yield 29 g (37%).
The physico-chemical characteristics of this product are as follows:
"P-NMR (CDCI,) 15.52 ppm 'H-NMR (CDC13):
2 ppm Protons Multiplicity Assignation o 1.27 12H m CH;
4.21 8H m CHz 4.78 1H - d NH
5.57 1H dt CH
6.52 1H d CH Carom) 6.67 1H m CH (arum) 7.44 1H m CH (arum) 8.11 1H d CH Carom) ,. CA 02192456 2005-03-24 wo 9sr~4ss ~ rcr~sroo3ts Mass Spectrum (Ei Mass): .
334 M- I:tOH
243 M- P(O)(OCiHs)z F.xampk 2 Preparation of [[(5-Chloro-2-pyridinyl)amino]methylidene]-bisphosphonic acid io 5-chloro-2-amir~opyridine (0.2 moles) was mixed with triethyl orthoformate (0.8 mol) _.
and boron trifluoride etherate and the mixture was heated at 150° C for 4 h. The formed ethanol was distilled off during the reaction. Triethylorthoformate was distilled off in vacuum. Diethylphosphibe (0.4 mol) was added to the reaction mixture, and the mixt<u~e was .heated at 150° C while disrOling off the ethanol formed. The mixture was cooled and the raw product was purified chmmato-graphically (eluent dichloromdhane-methanol, 1:1). Yield 26.5 g (32 96). (31-P-NMR 15.20 ppm; CDCI~
2 o In the same manner may be pfd:
[[(3,5-dichIoro-2-pyridinyl)amino]methylidene]bisphosphonic acid tettsethylester (31-P-NMR 14.59 ppm; CDCI~
2 s [[(3-Chloro-S-trifluorom~hyl-pyridinyl)amino]m~hylidene]- bisphosphonic acid tetraexhylester (31-P-NMR 14.15 ppm; CDCI~
[[(5-Hydroxy-2-pyridinyl)amino]methylideae]bisphosphonic acid tetraethylester (Mass Spoctrum (EI Mass): 396 M, 35D M- EtOH, 259 M P(O)(OC=H')~
[[(5-Nitro-2-pyridinyl)amino]methylidene)bisphosphonic acid tetraethylestes (31-P-NMR 13.97 ppm; CDCIs) wo ~ pcrr~sroo3is a [(5-Benzyloxy-2 pyridinyl)amino]methylidene]bisphosphonic acid retiaethylester [[(5-Methaxy 2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(3,5-Dimethaay 2 pyridinyl)amino]methylidene]bisphos phonic acid taraethyles-ter F~amltle 3 1 o Preparation of [[(3-Hydtnxy-2 pyridinyl~nino]methylidene]-bisphosphonic acid tettaetbylester 2-Amino-3-hydroxypyridine was O-ba~zylated with beazylchloride in a two phase system and phase transfer catalyst (&istol et al, Synthesis 1981, 971). 2-Amino-3-' benzyloxypyridine (0.I mol) was dissolved in dichio~romethana and the solution was cooled tow0° C 50 ml Formic acid/axxicanhydride (5:3) was addod to the solution, and the mixture was slimed overnnght at room temperature. The reaction mixture was abated, and the residue was washed with di-isopt~opyldher to give 11.4 g 3-benzyloxypyridinyl-2-formamide. 10 ml Phosghoroustrichloride and 1.5 ml 2o triethylphosphite was heated at 60° -?0° C for 1 hour. 3-Henzyloxygyridyl-2-formamide (0.01 mol) was addod to the solution, and the mixture was stir~d far five hours at room tangaature. The ion mixture was cmroentrated and puri-fied chromatogtaphicallY (eluent dichloromethane-mahanol, 2:1) to get 0.8 g [
f (3-benzyloxy 2 pyridinylo]methylidene]bisphosphorcic acid tetiraethylester. The benzylgroug was hydrogenated to get 0.4 g [[(3-Hydroxy 2 pyridinyl)amino]methy-lidene]-bisphosphonic acid Z~thylesOes (Mass Spearum (LI Mass): 396 M, 350 M- EtOH, Z59 M- P(O)(z In the same manner may be prepared:
[[(6-Benzyloxy 3-pyridinyl)amino]methylidene]bisphosphonic acid tetracthylester WO 95133466 pCTIF195100315 j[(6-Hydroxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester Example 4 Preparation of [[(6-Chloro-3-pyridinyl)amino]methylidene]-bisphosphonic acid tetraethylester Diethyl iodomethylphosphonate was prepared according to Cade, J. Chem.Soc.
1959; 2266.
to 6-Chloro-3-aminopyridine was alkylated with diethyl iodomethylphosphonate, sodium amide as base, with lrnown methods. The obtained 6-chloro-3-pyridinyla-mino-methylphosphonic acid diethylester (0.5 mol) and N-bromosuccinimid (0.5 mot) in anhydrous carbontetrachloride is irradiated 2 hours with a 200 W lamp.
The solid is filtered off, washed with carbontetrachloride and the solution is con-centrated in vacuo. The obtained 6-chloro-3-pyridinylamino(bromomethyl)-phos-phonic acid diethylester (0.1 mol) is warmed in tetrahydrofuran with triet-hylphosphite (0.1 moI) in 50° C for 4 hours. The reaction mixture is concentrated in vacuo. The product is purified chromatographically (eluent dichloromethane:
2o methanol 9:1). Yield 5.1 g.
In the same manner may be prepared:
jj(2-Chloro-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(6-Methoxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [(4-Pyridinylamino)methylidene]bisphosphonic acid tetraethylester 3 o j[(6-Amino-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(3-Nitro-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(2-Chloro-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester [[(5-Acyloxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester r Effect on spontaneous bone resorption assessed by urinary tetracycline excreti-on from prelabeled rats Male Sprague-Dawley rats were used. From the first week of life, the rats were 1o injected subcutaneously with a solution containing 10 WCi/ml of (7-'H(I~)tetracy-cline dissolved in physiological saline. The injections were performed twice week-ly for 6 weeks. Every animal received a total amount of 20 ~Ci radiolabeled tetracycline. All animals were given normal diet for growing animals and water ad libitum. One week after the last injection of radiolabeled tetracycline, the rats were >.5 weighed and feeding with diet for adult animals was started. At fifth day the rats were randomized into groups and housed in individual metabolic cages. 24-h urine collections were performed for ten days. From the second day [(2-pyridinylami-no)methylidene]bisphosphonic acid tetraethylester, compound I, dissolved in phy-siological saline was injected subcutaneously at different dose levels daily for six 2 o days. Control animals received physiological saline. Urine volume was measured and the radioactivity in urine samples was determined by liquid scintillation coun-ting. The data was calculated as the ratio of treated/control at each day for the determination of maximal inhibition of tetracycline excretion.
25 Excretion of unmetabolized tetracycline into urine reflects its removal from bone during resorptive processes and thus enables the continual monitoring of bone resorption. As shown in Table 1 (compound I) dose-dependently inhibited exc-rrztion of radiolabeled tetracycline indicating inhibition of bone resorption.
W095133466 2~ 92456 pCT~5100315 Table 1 Effect on spontaneous bone resorption in rats Inhibition of tetracycline excretion ' n Mean (SE) I 1 mg/kg 5 12.2 (6.4) 10 mglkg 5 19.8 (5.9) 100 mg/kg 5 50.0 (6.1) 200 mg/kg 5 72.9 (2.~
Effect on immobilization induced osteoporosis in rats Male Sprague-Dawley rats weighing 200125 g were randomized by weight into groups and anesthetized with Hypnorm/Mebunat and Temgesic. A dorsolateral to incision was made on the right or left hip through which the sciatic nerve was exposed, and a 0.5 cm section excised. The muscle and skin were sutured and the animal returned to its cage. The contralateral leg was left intact. The compound I
dissolved in physiological saline was administered by subcutaneous injection daily at different dose levels from two days before the surgery until the day of 20 postneurectomy. Control animals received physiological saline. Animals double-labeled with fluorochrome at standardized time points were sacrificed at 21 days postneurectomy and their femora were removed. Femora were embedded in met-hylmetacrylate, sectioned, and stained. The metphyseal secondary spongiosa and the diaphyseal cortical bone of the femora were subjected to histomorphometric 2 o analysis. In control rats, femoral total bone area decreased in the immobilized leg.
As shown in Table 2 the compound I increased dose-dependently femoral bone area in the immobilized leg. No deleterious effects on mineral apposition rate of cortical bone were shown (data not presented).
wo ~~ss rcr~oo3is Table 2 ,Effect on immobilization induced osteoporosis in rats . Immobilized , leg Femur total bone area 96 , , n Mean (SE) Control 20 5.3 (O.ti) I 1 mglkg 4 6.0 (1.3) 37,5 mglkg 5 17.3 (2.0) ' 75 mg/kg 5 ' 24.5 (2.5) .200 mg/kg 7 . 35.5 (1.7) 1o Et~ect on bone in vitro Newborn mitt were labeled by a subcutaneous injection of 'sCa four days prior to saciifioe. Calvarial bone fragtneats were miaodissected from the parietal bones, prancubated in culture medium with indomethaein, washed and then cultured for three days with and without the compound I. Hone resorption was stimulated by parathyroid hormone (PT~i, 10 nM) and an intubitory effect on this stimulated resorption was measured. As presaited in Table 3 no inhibition of resorption in vitro was shown except at very high, unphyaiological eonc~trations. For the determination of the binding of compound I to bone mineral, '4C-disodium elod-2 G ronate tetrahydrate and hydroxyapatite crystals were incubated at room temperature in barbituric acid buffer at physiological pH in the absence and pea of the compound I in various concentrations. Aftea two hours incubation, the mixture was centrifuged, and the percent of the total specifically bound radioactivity was measured from the supernatant. No binding of the compound I to hydroxyapatite W095/33466 2192456 P~~~00315 was found at up to 500 ~cM concentration (Table 3).
Table 3 Effect on bone in vitro Inhibition of PT'II-sti-Binding to bone mulated resorption mineral 100 (PTH-x)/PT'fi Inhibition R'o (SE) I 1 ~cmolll No inhibiton N.D.
5 pmol/I N.D. No binding 10 ~.mol/1 No inhibition N.D.
100 pmol/I No inhibition No binding 200 ~mol/l N.D. No binding 500 pmol/1 N.D. No binding 1000 ~.mol/112.9 (1.3) N.D.
N.D. = Not determined Pharmacokinetics Bioavailability was determined from the total amount of compound excreted into urine during 24 hours or from the serum concentration data at different time points after oral administration and intravenous administration. The urine and serum samples were analyzed for the test compound I with high pressure liquid chroma-tographic methods. Below 10Y~ of the oral dose and 14% of the intravenous dose was excreted as a parent compound during 24 hours (Table 4, bioavailability 5$%). BioavaiIability of compound I assessed by serum concentration data was 44~.
WO 95133466 PCT1Fd95/00315 z~ 9za.56 Table 4 Urinary excretion, AUCa,m, and bioavailability of I
after a single intravenous or oral dose*
Excretion AUCo-, ~, 0-24 h '3'0 of doseF % h * ~g/ml F % , p.o. 7.8 58 60.7 44 i.v. 13.6 138.7 Dose 114 mg/kg F = bioavailability to AUC0.,~, = Area under the blood level-time curve
Claims (9)
1. Pyridinyl-aminomethylidenebisphosphonic acid tetraesters of the formula I
in which formula each of R1 to R4 is a straight or branched saturated C1-C5-alkyl group, each of X and Y is independently hydrogen, straight or branched saturated C1-alkyl group, halogen, hydroxyl, C1-C5-alkoxy, benzyloxy, acyloxy, nitro, trifluoro-methyl group or NR5R6, wherein R5 and R6 are the same or different and are hydrogen, C1-C5-alkyl or-acyl, for use as therapeutically active agents in treating bone diseases selected from osteolytic bone diseases due to malignancy, Paget's disease, and primary and secondary osteoporosis.
in which formula each of R1 to R4 is a straight or branched saturated C1-C5-alkyl group, each of X and Y is independently hydrogen, straight or branched saturated C1-alkyl group, halogen, hydroxyl, C1-C5-alkoxy, benzyloxy, acyloxy, nitro, trifluoro-methyl group or NR5R6, wherein R5 and R6 are the same or different and are hydrogen, C1-C5-alkyl or-acyl, for use as therapeutically active agents in treating bone diseases selected from osteolytic bone diseases due to malignancy, Paget's disease, and primary and secondary osteoporosis.
2. Compound according to formula I of claim 1, wherein C1-C5-alkyl, the alkyl group in the alkoxy and the acyl group, has the meaning of methyl or ethyl, and halogen has the meaning of chlorine.
3. Compound according to claim 1 or 2 for use as a therapeutically active agent, wherein the groups R1 to R4 are the same.
4. Compound according to claim 3 for use as a therapeutically active agent, whe-rein the pyridinyl group is 2-pyridinyl.
5. Compound according to claim 1 for use as a therapeutically active agent, which is [(2-pyridinylamino)methylidene]bisphosphonic acid tetraethylester, [[(3-Hydroxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(6-Methoxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [(4-Pyridinylamino)methylidene]bisphosphonic acid tetraethylester, ([(5-Chloro-2 pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(5-Methoxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(6-Amino-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(3-Nitro-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(3,5-Dichloro-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(6-Hydroxy-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(5-Hydroxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(3-Chloro-5-trifluoromethyl-pyridinyl]methylidene]-bisphosphonic acid tetraethylester, [((2-Chloro-3-pyridinyl)aminio]methylidene]bisphosphonic acid tetraethylester, [[(6-Chloro-3-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(3-Benzyloxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, [[(5-Nitro-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester, or [[(5-Benzyloxy-2-pyridinyl)amino]methylidene]bisphosphonic acid tetraethylester.
6. Compound according to any one of, the proceding claims for use in the treat-ment of bone diseases, selected from osteolytic bone diseases due to malignancy, Paget's disease and primary and secondary osteoporosis.
7, Pharmaceutical composition for the treatment of bone diseases, selected from osteolytic bone diseases due to malignancy, Paget's disease and primary and secondary osteoporosis, characterized in that it contains a pharmaceutically acceptable carrier and an effective amount of a compound according to any one of claims 1 to 5.
8. Use of a compound according to any one of the preceding claims 1 to 5 as the active agent for manufacturing a pharmaceutical composition for the treatment of bone diseases, selected from osteolytic bone diseases due to malignancy, Paget's disease and primary and secondary osteoporosis.
9. In the treatment of bone diseases selected from osteolytic bone diseases due to malignancy, Paget's disease and primary and secondary osteoporosis, by the use of an effective amount of a compound according to any one of claims 1 to 5 or of a composition according to claim 7.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9402001-3 | 1994-06-09 | ||
| SE9402001A SE9402001D0 (en) | 1994-06-09 | 1994-06-09 | Pyridyl bisphosphonates for use as a therapeutic agent |
| PCT/FI1995/000315 WO1995033466A1 (en) | 1994-06-09 | 1995-06-02 | Pyridylbisphosphonates for use as a therapeutical agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2192456A1 CA2192456A1 (en) | 1995-12-14 |
| CA2192456C true CA2192456C (en) | 2006-08-01 |
Family
ID=36764267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002192456A Expired - Lifetime CA2192456C (en) | 1994-06-09 | 1995-06-02 | Pyridylbisphosphonates for use as a therapeutical agent |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2192456C (en) |
-
1995
- 1995-06-02 CA CA002192456A patent/CA2192456C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2192456A1 (en) | 1995-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES8707543B9 (en) | Pharmaceutical compositions containing geminal diphosphonates. | |
| NL192562C (en) | Pharmaceutical preparation containing an NH2- (CH2) 3-C (PO3H2) 2OH compound. | |
| EP0325482A1 (en) | (Cycloalkylamino)methylenebisphosphonic acids and medicines containing them | |
| JPH026409A (en) | Oral medicine composition of a diphosphonic acid derivative | |
| US6083938A (en) | Pyridinylbisphosphonates for use as a therapeutical agent | |
| EP0354806A2 (en) | Heterocyclic bisphosphonic acid derivatives | |
| PL174726B1 (en) | Novel phosphonocaboxylane compounds and farmaceutic agent for treating improper metabolism of calcium and phosphates | |
| US4902679A (en) | Methods of treating diseases with certain geminal diphosphonates | |
| FI87652B (en) | FRAMEWORK FOR THE FRAMSTATION OF THE OCTAHYDROPYRIDINDIPHOSPHONY PHARMACEUTICAL FORM OF THE SALT OF THE ESTRAR DAERAV | |
| JPS63239291A (en) | Novel heterocyclically substituted diphosphonate compound, medicinal composition and therapy of calcium and phosphate metabolism abnormality | |
| JPS637526B2 (en) | ||
| JP2568999B2 (en) | Pharmaceutical composition containing gem-diphosphonate | |
| CA2192456C (en) | Pyridylbisphosphonates for use as a therapeutical agent | |
| MXPA96006180A (en) | Piridilbisphosphonates to be used as a therapist agent | |
| JPH02104593A (en) | Combination of medical compound with diphosphonic acid derivative | |
| FI117053B (en) | New pyridinyl-amino:methylidene bis:phosphonic acid derivs. - used to treat bone disease e.g. osteolytic bone diseases due to malignancy, Paget's disease and osteoporosis | |
| US3703579A (en) | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue | |
| DK173973B1 (en) | Geminal heterocyclic diphosphonic acids and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the same | |
| WO2001030788A1 (en) | Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use | |
| Schwartz | Recent advances in calcium and phosphorus metabolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20150602 |
|
| MKEX | Expiry |
Effective date: 20150602 |